Stay updated on Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial

Sign up to get notified when there's something new on the Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The page’s interface/build version was updated from v3.5.2 to v3.5.3 without changing the displayed study details.
    Difference
    0.1%
    Check dated 2026-04-24T06:39:48.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    - Revision updated from v3.5.0 to v3.5.2.
    Difference
    0.1%
    Check dated 2026-04-17T02:50:45.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    Added a link to the Genetic and Rare Diseases Information Center resources for squamous cell carcinoma of the head and neck, and a related topic entry for head and neck squamous cell carcinoma.
    Difference
    0.2%
    Check dated 2026-04-02T15:36:16.000Z thumbnail image
  5. Check
    37 days ago
    Change Detected
    Summary
    Revision: v3.5.0 added; Revision: v3.4.3 removed.
    Difference
    0.1%
    Check dated 2026-03-19T05:08:36.000Z thumbnail image
  6. Check
    44 days ago
    Change Detected
    Summary
    The page revision label was updated from v3.4.2 to v3.4.3 in the header.
    Difference
    0.1%
    Check dated 2026-03-12T02:34:13.000Z thumbnail image
  7. Check
    72 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2. Removed the government funding lapse notice and the v3.4.1 revision entry.
    Difference
    0.5%
    Check dated 2026-02-11T14:25:48.000Z thumbnail image

Stay in the know with updates to Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial page.